GCAR and Purdue initiate GBM AGILE trial of tinostamustine
The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma have announced the activation of tinostamustine in the Glioblastoma Adaptive …
Post
-
-
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive …
-
UK launches programme to improve dementia clinical trial enrolment
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has invited …
-
German study shows promising results for online depression counselling
Clinical depression represents a major public health challenge whose diagnosis and treatment are frequently hindered by social stigma or patient …
-
Insmed freezes Brinsupri’s HS programme on Phase II failure
Insmed is putting a stop to the development of Brinsupri (brensocatib) in hidradenitis suppurativa (HS) after the drug failed to …
-
NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer’s
NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease treatment. The randomised, double-masked …
-
First patient dosed in CatalYm’s Phase IIb visugromab trial
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab, along with chemoimmunotherapy as a …
-
Sanofi’s bispecific scores in respiratory diseases but fails in eczema
Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic …
-
Artificial intelligence is welcome, but minimization isn’t? A clinical paradox
Artificial intelligence has become a familiar topic in clinical trial discussions. Sponsors increasingly ask about automation, predictive insights, and smarter …
-
Why Timelines Break Down in Rare Kidney Drug Development
Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial …
-
TRiCares gains FDA IDE to initiate tricuspid regurgitation treatment pivotal trial
TRiCares has been granted an investigational device exemption (IDE) by the US Food and Drug Administration (FDA) to initiate a …
-
ACC 2026: Ventyx’s VTX3232 Phase IIa results show anti-inflammatory benefits in obesity
On 30 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana, …
-
Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD
Alar Pharmaceuticals’ long-acting, ketamine-based therapy has shown early signs of symptom improvement in treatment-resistant depression (TRD) in a Phase I …
-
Amgen reports positive Phase III findings for subcutaneous Tepezza trial
Amgen has reported positive top line results from its Phase III subcutaneous Tepezza (teprotumumab-trbw) trial in adults with moderate-to-severe active …
-
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption …
